Moderna Sharing Less Data Since IPO, CEO Says

The video discusses the evolution of a biotech company post-IPO, focusing on changes in data sharing, partnerships, and investor relations. It highlights the unique potential of mRNA technology in medicine, emphasizing its speed and efficiency in drug development. The discussion also covers the challenges of ensuring efficacy and the technological advancements that support the company's innovations.

What does the CEO say about the efficacy of the drugs being developed?

How does the CEO justify the approach of using the body to create treatments?

What technological advancements does the CEO credit for the company's capabilities?